The fibrinolytic system in neoplasia.
During activation of the fibrinolytic system plasminogen is converted to plasmin by tissue plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). t-PA is predominantly released from endothelial cells, u-PA primarily by renal parenchymal cells. The activation of plasminogen is regulated by plasminogen activator inhibitor-1 (PAI-1), plasmin is controlled by alpha 2-plasmin inhibitor. The fibrinolytic system is not only involved in the intravascular dissolution of fibrin (thrombi), it also plays a vital role in normal physiologic reproduction, wound repair, angiogenesis, and tissue remodeling. Fibrinolysis is also a vital component in the pathogenesis of neoplastic disease. It is essential in releasing cells from their primary site of origin, providing nutrition for neoplastic cell growth and promoting cell mobility and motility. In neoplastic cells the degradation of the extracellular matrix proteins is facilitated by excessive expression of u-PA, t-PA, and u-PAR. In many forms of carcinoma increased expression of u-PAR and u-PA is associated with significantly shorter survival. Greater expression of u-PA in breast cancer cells, for example, is associated with shorter survival and increased relapse rate. Progressively aggressive neoplastic cells evidence high expression of u-PA and u-PAR activities, variable expression of t-PA, and enhanced PAI-1 and PAI-2 activities. In acute nonlymphocytic leukemias, poor outcome correlates with high t-PA levels. In acute progranulocytic leukemia there is a high incidence of DIC. Neoplastic prostatic tissue also expresses high u-PA activity and the more aggressive the cell line, the greater the number of u-PAR and the higher the u-PA activity. In gynecologic malignancies, a greater expression of u-PA in combination with cathepsin D is associated with widespread disease and poor prognosis. High u-PA values were also seen in patients with brain, gastric, and hepatic malignancies. It is evident that the plasminogen-plasmin system is a vital component in the biology of neoplastic disease and that it is, in theses conditions, in no way beneficial to the host.
Bell
W R
WR
Department of Medicine/Division Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
D000818:Animals; D001779:Blood Coagulation Factors / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis; D013927:Thrombosis / Q000097:blood / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood / Q000378:metabolism
D001779:Blood Coagulation Factors; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator